| 1.09 0.03 (2.83%) | 07-26 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.61  |
1-year : | 1.86 |
| Resists | First : | 1.38 |
Second : | 1.6 |
| Pivot price | 1.21 |
|||
| Supports | First : | 1.02 |
Second : | 0.85 |
| MAs | MA(5) : | 1.09 |
MA(20) : | 1.24 |
| MA(100) : | 1.79 |
MA(250) : | 1.44 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 8.6 |
D(3) : | 6.2 |
| RSI | RSI(14): 31.9 |
|||
| 52-week | High : | 2.49 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ IINN ] has closed above bottom band by 15.7%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.14 - 1.15 | 1.15 - 1.16 |
| Low: | 1.01 - 1.02 | 1.02 - 1.03 |
| Close: | 1.08 - 1.09 | 1.09 - 1.1 |
Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation (MV) for the treatment of respiratory failure. Its lead product is the augmented respiration technology system (ART), a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. The company was incorporated in 2018 and is based in Ra'annana, Israel.
Thu, 11 Jul 2024
Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System - PR Newswire
Thu, 11 Jul 2024
Inspira™ Receives Israeli Regulatory Approval for the INSPIRA™ ART100 System - StockTitan
Mon, 17 Jun 2024
Inspira™ Introduces Advanced Life Support Solutions to Key International Leaders at the Annual iECMOs Conference in Israel - PR Newswire
Thu, 30 May 2024
Inspira™ Technologies Announces Business Targets Presentation Following FDA Clearance and Significant Developments - PR Newswire
Wed, 29 May 2024
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant - Yahoo Finance
Tue, 28 May 2024
Inspira Technologies’ Device Wins FDA Clearance - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 17 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 8.9 (%) |
| Held by Institutions | 0.5 (%) |
| Shares Short | 48 (K) |
| Shares Short P.Month | 200 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -59.6 % |
| Return on Equity (ttm) | -116.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.18 |
| PEG Ratio | 0 |
| Price to Book value | 2.94 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|